NASDAQ:ISEEIVERIC bio Stock Price, Forecast & News

$4.24

+0.05 (+1.19 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$4.10

Now: $4.24▼

$4.28

50-Day Range

$3.06

MA: $3.73▼

$4.40

52-Week Range

$0.91

Now: $4.24▼

$8.97

Volume386,484 shs

Average Volume497,585 shs

Market Capitalization$213.10 million

P/E RatioN/A

Dividend YieldN/A

Beta2.19

IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD). It is also developing High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitors for the treatment of GA secondary to dry AMD and other age-related retinal diseases, such as wet AMD and idiopathic polypoidal choroidal vasculopathy. The company has a license agreement with the University of Florida Research Foundation (UFRF) and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP); and Best disease and other bestrophinopathies. It also has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach to create AAV gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and STGD1; and to evaluate various AAV gene delivery methods for potential application in the eye. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

1.3 Analyst's Opinion

Consensus Rating
IVERIC bio has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.25, IVERIC bio has a potential downside of 70.5% from its current price of $4.24.
Amount of Analyst Coverage
IVERIC bio has received no research coverage in the past 90 days.

2.3 Community Rank

Outperform Votes
IVERIC bio has received 25 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IVERIC bio has received 29 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IVERIC bio has received 53.70% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IVERIC bio and other stocks. Vote “Outperform” if you believe ISEE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ISEE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IVERIC bio does not currently pay a dividend.
Dividend Growth
IVERIC bio does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IVERIC bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of IVERIC bio is held by insiders.
Percentage Held by Institutions
62.88% of the stock of IVERIC bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for IVERIC bio are expected to grow in the coming year, from ($1.18) to ($0.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IVERIC bio is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IVERIC bio is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IVERIC bio has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.05 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ISEE

Previous Symbol

CUSIPN/A

CIKN/A

Webivericbio.com

Phone212-845-8200

Debt

Debt-to-Equity RatioN/A

Current Ratio10.50

Quick Ratio10.50

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$209.98 million

Price / Sales1.01

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.08 per share

Price / Book2.04

Profitability

EPS (Most Recent Fiscal Year)($1.39)

Net Income$-58,860,000.00

Net MarginsN/A

Return on Equity-59.50%

Return on Assets-53.62%

Miscellaneous

Employees35

Outstanding Shares50,260,000

Market Cap$213.10 million

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive ISEE News and Ratings via Email

Sign-up to receive the latest news and ratings for ISEE and its competitors with MarketBeat's FREE daily newsletter.

IVERIC bio (NASDAQ:ISEE) Frequently Asked Questions

How has IVERIC bio's stock been impacted by COVID-19 (Coronavirus)?

IVERIC bio's stock was trading at $4.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ISEE stock has decreased by 4.9% and is now trading at $4.24. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IVERIC bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IVERIC bio.

When is IVERIC bio's next earnings date?

IVERIC bio is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for IVERIC bio.

How were IVERIC bio's earnings last quarter?

IVERIC bio Inc (NASDAQ:ISEE) released its earnings results on Wednesday, May, 6th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.11. View IVERIC bio's earnings history.

What price target have analysts set for ISEE?

3 equities research analysts have issued 12 month target prices for IVERIC bio's shares. Their forecasts range from $1.25 to $1.25. On average, they anticipate IVERIC bio's stock price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 70.5%. View analysts' price targets for IVERIC bio.

Has IVERIC bio been receiving favorable news coverage?

News stories about ISEE stock have been trending extremely negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. IVERIC bio earned a news sentiment score of -4.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutIVERIC bio.

Who are some of IVERIC bio's key competitors?

Some companies that are related to IVERIC bio include Gossamer Bio (GOSS), Omeros (OMER), Passage Bio (ORIC), Collegium Pharmaceutical (COLL), CannTrust (CNTTF), Cara Therapeutics (CARA), Kura Oncology (KURA), Kadmon (KDMN), Molecular Templates (MTEM), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Homology Medicines (FIXX) and Nabriva Therapeutics (NBRV). View all competitors.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Alibaba Group (BABA), Cronos Group (CRON), Cassava Sciences (SAVA), Tesla (TSLA), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Amplify Energy (AMPY), Amplify Energy (AMPY) and Dominion Energy (D).

Who are IVERIC bio's key executives?

IVERIC bio's management team includes the following people:

Dr. David R. Guyer, Exec. Chairman (Age 59)
Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 63)
Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 58)
Mr. David F. Carroll, Sr. VP, CFO & Treasurer (Age 53)
Mr. Keith Westby M.B.A., Sr. VP & COO (Age 44)

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

Who are IVERIC bio's major shareholders?

IVERIC bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include VR Adviser LLC (5.15%), Stonepine Capital Management LLC (5.14%), Soleus Capital Management L.P. (3.20%), Burrage Capital Management LLC (3.03%), Perceptive Advisors LLC (2.74%) and Perceptive Advisors LLC (2.74%). Company insiders that own IVERIC bio stock include David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View institutional ownership trends for IVERIC bio.

Which institutional investors are selling IVERIC bio stock?

ISEE stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Morgan Stanley, Stonepine Capital Management LLC, Orbimed Advisors LLC, Burrage Capital Management LLC, Invesco Ltd., Connor Clark & Lunn Investment Management Ltd., and Summit X LLC. Company insiders that have sold IVERIC bio company stock in the last year include David Francis Carroll, David R Guyer, and Keith Westby. View insider buying and selling activity for IVERIC bio.

Which institutional investors are buying IVERIC bio stock?

ISEE stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, Soleus Capital Management L.P., Deutsche Bank AG, Perceptive Advisors LLC, Perceptive Advisors LLC, Two Sigma Investments LP, Bogle Investment Management L P DE, and Ghost Tree Capital LLC. View insider buying and selling activity for IVERIC bio.

How do I buy shares of IVERIC bio?

Shares of ISEE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $4.24.

How big of a company is IVERIC bio?

IVERIC bio has a market capitalization of $213.10 million and generates $209.98 million in revenue each year. The company earns $-58,860,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. IVERIC bio employs 35 workers across the globe.

What is IVERIC bio's official website?

The official website for IVERIC bio is ivericbio.com.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company can be reached via phone at 212-845-8200 or via email at [email protected]

This page was last updated on 5/24/2020 by MarketBeat.com Staff